Prothena Corporation plc PRTA
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery and development of novel therapies targeting protein dysregulation, particularly in neurodegenerative diseases and rare peripheral amyloid diseases. The company leverages deep expertise in the biology of misfolded proteins …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryIreland
Employees67
TickerPRTA
Statistics
Market Cap$449.3M
Revenue (TTM)$9.7M
Net Income-$244.1M
Net Margin-2520.6%
EPS$-2.81
P/E-1.82
P/S7.46
P/B1.40
EV/EBITDA-1.00
ROE-40.3%
Dividend Yield2.42%
Price$8.46
Data: Twelve Data · Revenue = mcap / P/S